Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
Open accessAbstract
Introduction: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy as measured by volumetric magnetic resonance imaging (MRI). Methods: In the EXPEDITION3 phase 3 trial, participants with mild Alzheimer's disease were randomized to receive intravenous infusions of either 400 mg of solanezumab or placebo every 4 weeks for 76 weeks. Volumetric MRI scans were acquired at baseline and at 80 weeks from 275 MRI facilities using a standardized imaging protocol. A subset of 1462 patients who completed both MRI and 14‐item Alzheimer's Disease Assessment Scale–Cognitive Subscale assessments at both time points were selected for analysis. Longitudinal MRI volume changes were analyzed centrally by tensor‐based morphometry with a standard FreeSurfer brain parcellation. Prespecified volumetric measures, including whole brain and ventricles, along with anatomically localized regions in the temporal, parietal, and frontal lobes were evaluated in those participants. Results: Group‐mean differences in brain atrophy rates were directionally consistent across a number of brain regions but small in magnitude (1.3–6.9% slowing) and not statistically significant when corrected for multiple comparisons. The annualized rates of change of the volumetric measures and the correlation of these changes with cognitive changes in placebo‐treated subjects were similar to those reported previously. Discussion: In the EXPEDITION3 trial, solanezumab did not significantly slow down rates of global or anatomically localized brain atrophy. Brain volume changes and their relationship to cognition were consistent with previous reports.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · see citing works
Self-citationAvants, B., Epstein, C. L., Grossman, M., & Gee, J. C. (2007) · Medical Image Analysis · doi:10.1016/j.media.2007.06.004 · Cited by 5,618 · see citing works
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153 · see citing works
Self-citationTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · see citing works
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · see citing works
Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia
Du, A., Schuff, N. W., Kramer, J. H., Rosen, H. J., Gorno‐Tempini, M. L., Rankin, K. P., Miller, B. L., & Weiner, M. W. (2006) · Brain · doi:10.1093/brain/awm016 · Cited by 479 · see citing works
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · see citing works
Self-citationThe Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Sabuncu, M. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.167 · Cited by 360 · see citing works
Symmetric Log-Domain Diffeomorphic Registration: A Demons-Based Approach
Vercauteren, T. K., Pennec, X., Aymeric Perchant, B., & Ayache, N. (2008) · Lecture notes in computer science · doi:10.1007/978-3-540-85988-8_90 · Cited by 356 · see citing works
The cortical signature of prodromal AD
Bakkour, A., Morris, J. C., & Dickerson, B. C. (2008) · Neurology · doi:10.1212/01.wnl.0000340981.97664.2f · Cited by 315 · see citing works
Self-citationBapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304 · see citing works
Dickerson, B. C., Wolk, D. A., & Initiative, T. A. D. N. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199505 · Cited by 139 · see citing works
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes
Beckett, L. A., Harvey, D. J., Gamst, A. C., Donohue, M., Kornak, J., Zhang, H., Kuo, J. H., & Initiative, A. D. N. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.002 · Cited by 119 · see citing works
Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment
McDonald, C. R., Gharapetian, L., McEvoy, L. K., Fennema‐Notestine, C., Hagler, D. J., Holland, D., & Dale, A. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.015 · Cited by 111 · see citing works
Abushouk, A. I., Elmaraezy, A., Aglan, A. D., Salama, R., Fouda, S., Fouda, R., & AlSafadi, A. M. (2017) · BMC Neurology · doi:10.1186/s12883-017-0850-1 · Cited by 84 · see citing works
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 83 · see citing works
Salloway, S., Sperling, R. A., Gregg, K. M., Yu, P., Joshi, A. D., Lu, M., Mintun, M. A., Pontecorvo, M. J., Booth, K., Wyman, B. T., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.250 · Cited by 12 · see citing works
Self-citationDean, R. A., Shaw, L. M. J., Waligórska, T., Korecka, M., Figurski, M., Trojanowski, J. Q., Sundell, K. L., Andersen, S. W., Holdridge, K. C., Lachno, D. R., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1591 · Cited by 7 · see citing works
Self-citationBiomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
Russu, A., Samtani, M. N., Xu, S. X., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Liu, E., Brashear, H. R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151065 · Cited by 5 · see citing works
Novak, G., Einstein, S. G., Lü, Y., Tudor, I. C., Gregg, K. M., Collins, P., Wyman, B. T., Yuen, E., Nielsen, C. F., Grundman, M., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.583 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988 · see citing works
“Although solanezumab was well tolerated in the participants, it was not able to show the significant therapeutic benefits to AD patients.(345,346) The failure may be due to the too low concentrations of the antibody reaching to the brain.”
BackgroundSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works
“consistent with literature reports for other amyloidtargeting agents [22–24], the reasons for these observations are unclear, but may be related to antibody profile and Aβ clearance, as has been suggested previously [25].”
ResultJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330 · see citing works
Abbas, S. Q., Chi, L., & Chen, Y. P. (2022) · Pattern Recognition · doi:10.1016/j.patcog.2022.109031 · Cited by 81 · see citing works
Pemberton, H., Zaki, L. A. M., Goodkin, O., Das, R., Steketee, R. M. E., Barkhof, F., & Vernooij, M. W. (2021) · Neuroradiology · doi:10.1007/s00234-021-02746-3 · Cited by 80 · see citing works
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77 · see citing works
Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 77 · see citing works
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 68 · see citing works
The Future of Anti-Amyloid Trials
Aisen, P. S. S., Cummings, J. L., Doody, R. S., Kramer, L. D., Salloway, S., Selkoe, D. J., Sims, J. R., Sperling, R. A., & Vellas, B. J. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.24 · Cited by 60 · see citing works
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56 · see citing works
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 51 · see citing works
Schiffmann, R., Cox, T., Dedieu, J., Gaemers, S. J. M., Hennermann, J., Ida, H., Mengel, E., Minini, P., Mistry, P., Musholt, P., et al. (2022) · Brain : a journal of neurology · doi:10.1093/brain/awac379 · Cited by 33 · see citing works
Self-citationTouroutoglou, A., Katsumi, Y., Brickhouse, M. J., Zaitsev, A., Eckbo, R., Aisen, P. S. S., Beckett, L. A., Dage, J. L., Eloyan, A., Foroud, T., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13466 · Cited by 47 · see citing works
Self-citationPemberton, H., Goodkin, O., Prados, F., Das, R., Vos, S. B., Moggridge, J. C., Coath, W., Gordón, E., Barrett, R., Schmitt, A., et al. (2021) · European Radiology · doi:10.1007/s00330-020-07455-8 · Cited by 42 · see citing works
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., 高晶晶, Budda, B., Park, L. Q., Gupta, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04273-1 · Cited by 45 · see citing works
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 40 · see citing works
Self-citationNonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35 · see citing works
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 34 · see citing works
Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data
Nader, C. A., Ayache, N., Frisoni, G. B., Robert, P. H., Lorenzi, M., & Initiative, A. D. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab091 · Cited by 20 · see citing works
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18 · see citing works
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19 · see citing works
ten Kate, M., Barkhof, F., & Schwarz, A. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.92 · Cited by 15 · see citing works
Self-citationPET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 13 · see citing works
Multiparametric Quantitative Imaging Biomarker as a Multivariate Descriptor of Health: A Roadmap
Raunig, D. L., Pennello, G. A., Delfino, J. G., Buckler, A. J., Hall, T. J., Guimarães, A. R., Wang, X., Huang, E. P., Barnhart, H. X., deSouza, N. M., et al. (2022) · Academic Radiology · doi:10.1016/j.acra.2022.10.026 · Cited by 12 · see citing works
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 11 · see citing works
Clinical gene therapy development for the central nervous system: Candidates and challenges for AAVs
Leong, T. W., Pal, A., Cai, Q., Gao, Z., Li, X., Bleris, L. G., Hayenga, H. N., & Qin, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.009 · Cited by 7 · see citing works
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6 · see citing works
Petersen, K. K., Nallapu, B. T., Lipton, R. B., Grober, E. H., & Ezzati, A. (2024) · Neuroimage Reports · doi:10.1016/j.ynirp.2024.100227 · Cited by 5 · see citing works
Svaldi, D. O., Higgins, I. A., Holdridge, K. C., Yaari, R., Case, M. G., Bracoud, L., Scott, D., Shcherbinin, S., & Sims, J. R. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12313 · Cited by 4 · see citing works
Self-citationKim, Y. J., Lim, H.-S., Kim, J., Na, M., & Jeong, S. (2020) · Natural Product Communications · doi:10.1177/1934578x20924859 · Cited by 3 · see citing works
Armansyah, N. A., Putri, A. M., Azizah, W. N., & Maryati, I. (2023) · JURNAL PENDIDIKAN KEPERAWATAN INDONESIA · doi:10.17509/jpki.v9i1.52874 · Cited by 2 · see citing works
Pieperhoff, L., Lorenzini, L., Mastenbroek, S. E., Tranfa, M., Shekari, M., Wink, A. M., Wolz, R., Grootoonk, S., Ritchie, C. W., Boada, M., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103912 · Cited by 1 · see citing works
Dadsena, R., Costa, A. S., David, S., Haberl, L., Schulz, J. B., Reetz, K., & Haeger, A. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70233 · Cited by 1 · see citing works
Pieperhoff, L., Lorenzini, L., Almeida, F., Tranfa, M., Bollack, A., Arunachalam, P., Masserini, F., Wolz, R., Grootoonk, S., Ritchie, C. W., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71609 · Cited by 1 · see citing works
Ramírez, U. A. T., Medina, M. E., Ruiz, A. P. R., Borja, M. D. L. Á. S., & Ricoy, O. U. D. (2021) · Lux Médica · doi:10.33064/48lm20212964
Dadsena, R., Costa, A. S., David, S., Haberl, L., Schulz, J. B., Reetz, K., & Haeger, A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71651
- Authors
- Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., Dickerson, B. C., & Siemers, E. R.
- Affiliations
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
- BioClinica (United States) (US)
- Bioclinica Lyon France
- Avid Radiopharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Charil, Arnaud
- ORCID
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2019-01
- Volume
- 5
- Issue
- 1
- Pages
- 328-337
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6675941
- OpenAlex
- W2964503732
- Cited by
- 40
- References
- 26
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 1
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- solanezumab, mild Alzheimer's disease, brain atrophy, amyloid-beta, volumetric MRI, tensor-based morphometry, brain volume changes, cognitive decline, anti-amyloid therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
